Adalvo has successfully launched Dimethyl Fumarate (DMF) across various markets, serving over 20 partners on three continents.
Dimethyl Fumarate 120mg and 240mg hard capsules have been developed based on the reference brand Tecfidera, which is indicated in the treatment of relapsing-remitting multiple sclerosis. The product achieved global sales of approximately $1661 million in 2023, according to IQVIA.
Adalvo's robust supply chain ensures that our partners receive high-quality, differentiated products. Our extensive network and strategic partnerships reinforce our ability to meet market demands on a global scale, making us a reliable one-stop-shop platform for pharmaceutical solutions.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!